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Dear editor
Guertin et al1 argue in their article “Bias within economic evaluations” that if researchers 
fail to incorporate the future availability of generics entrants for new patented drugs, 
the incremental cost-effectiveness ratio (ICER) will be overestimated.1 Before address-
ing the validity of this argument, it is first worthwhile to consider the nature of both 
bias and economic evaluation.
Bias occurs due to an “error in the conception and design of a study … leading to 
results or conclusions that are systematically (as opposed to randomly) different from 
truth.”2 The concept of bias is therefore specific to the purpose of the specific study 
and the question or decision problem it is designed to address. Economic evaluations 
address decision problems specific to individual decision makers through considering 
the opportunity cost associated with alternative decision options relating to the adop-
tion of a technology at the time of the analysis.
Guertin et al challenge the use of current prices of branded pharmaceuticals in 
evaluating whether or not to fund them. They suggest that analysis should allow for the 
future availability of lower-cost generic equivalents. Before challenging the premise 
of this argument, it is worth considering the analytical approach adopted.
The authors assume that generics will become available at the expiry of the exist-
ing patent. In their case study of dabigatran, the patent expires in 2018.3 However, the 
availability of generic entrants is affected by the efforts of manufacturing companies 
to “evergreen” the patent.4 In 2011, additional patents were granted for dabigatran 
extending patent protection through 2024.3 The authors’ assumption of the earliest 
possible date for generic entry leads to the lowest possible estimate of the ICER.
The authors assumed that the cost of the generic equivalent would be 25% of the 
brand price. In some jurisdictions (such as Ontario as cited by Guertin et al), the cost 
of generic equivalents is set at a fixed percentage of the brand; however, as is the case 
in Ontario, this is frequently a function of the number of generic entrants approved for 
funding. The authors’ assumption of the lowest possible cost for a generic equivalent 
leads to the lowest possible ICER.
The authors addressed the latter two issues with limited sensitivity analysis. Further, 
assumptions relating to persistence and mortality rates used in the case study were also 
biased in favor of lowering the ICER, which despite the illustrative nature of the care study 
for the authors’ arguments may speak to larger issues of bias in economic evaluations.
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Thus, on further exploration, assumptions made in 
the article led to the lowest possible estimate of the incre-
mental cost of dabigatran, suggesting bias in the approach 
adopted.
Although we have demonstrated the problems in con-
ducting such an analysis, it should be highlighted that the 
approach is fundamentally flawed in that it ignores the true 
context of the decision problem – whether or not to fund the 
technology now at the current price. The decision problem 
facing decision makers is specific to a particular timepoint – 
decision makers are concerned with whether a technology 
currently represents an appropriate use of scarce health care 
resources. Decision makers can make alternate decisions at 
later timepoints, but this relates to alternate decision problems 
that can be addressed by further evaluation. The decision to 
fund or not fund a particular technology, at a given time, 
should not preclude an alternate decision at a later timepoint 
when the context and/or the information have changed. Thus, 
if a product is not cost-effective at the current brand cost but 
may be at the generic price, it will be optimal for decision 
makers to not fund it at the current time but consider revis-
ing their decision at a future date, once a generic becomes 
available.
Guertin et al appear to raise an interesting point for 
discussion. However, what the authors criticize in their 
article is not bias in the conduct of economic evaluation but 
a true representation of the decision problem facing decision 
makers. Economic evaluations are designed to assist in 
making optimal decisions, thus maximizing the health ben-
efits to be obtained from scarce health care resources. The 
approach suggested in this article is biased in both applica-
tion and design and will lead to bias in the estimation of the 
true value of products, thus leading to nonoptimal resource 
allocation.
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Dear editor
We welcome the opportunity to reply to the letter by Lee 
et al in order to dispute some of the claims they make about 
our paper.1 In their letter, Lee et al first propose a definition 
of the term “bias,” hinting that our choice of words within 
our title was inappropriate. We wish to remind Lee et al of 
a different definition of the term “bias”: “A range of factors 
that systematically influence the measures undertaken inde-
pendent of the studied intervention; a tendency, intentional or 
unintentional, to inappropriately or unfairly favor one or more 
of the interventions being evaluated.”2 As such, we maintain 
our position that bias does occur if the time to introduction of 
the generic entrant is applied differentially to the new drug 
than to the comparator drug.
Following this previous point, Lee et al go on to question 
our assumption that generic entrants of patented drugs would 
enter the market once the first patent of the drugs expire.1 We 
agree with Lee et al that there is uncertainty regarding the 
exact moment when generic entrants of patented drugs will 
arrive and that this may not be at the time of expiration of 
their first patent. Indeed, there have been situations where the 
generic entrants arrived prior to the expiration of the patents 
and cases where they arrived later. Since the exact date of 
appearance of the generic entrants cannot be determined 
when the economic evaluation is being submitted, we believe 
that it would be good practice to deal with this uncertainty 
through the use of sensitivity analyses.
Finally, Lee et al argue that “The decision problem fac-
ing decision makers is specific to a particular timepoint.” 
We would like to remind Lee et al that the 2006 Canadian 
Guidelines for the Economic Evaluation of Health Technolo-
gies state that “It is good practice to anticipate future com-
parators, particularly lower cost technologies that may enter 
the market within the timeframe relevant to the analysis.”3 
Furthermore, most decision makers require that economic 
evaluation be conducted with timeframes of 10 years or 
more and budget impact analyses which extend for 3 years 
or more. We thus strongly believe that the time of generic 
entry of a new drug should be taken into consideration within 
an economic evaluation and this practice is consistent with 
the 2006 Canadian Guidelines for the Economic Evaluation 
of Health Technologies. However, in the event that Lee et al 
still feel that the decision to fund or not a technology should 
be solely dependent on the current cost of both comparators, 
they should recommend that the next edition of the Canadian 
Guidelines on the Economic Evaluation of Health Technolo-
gies eliminate all reference to the future introduction of any 
generic entrants within the relevant time-horizon of the 
economic evaluation.4
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